CLDN18 and gastric cancer: In advanced GC types, represented by the Cldn18‐CreERT2; Apcfl/fl; Trp53fl/fl (Cldn18‐AT) mice,[17] we found that LZQ‐02‐023‐01 significantly reduced tumor burden and progression (Figure 6g).